Pharma Fundamentals: Utilizing Artificial Intelligence in Drug Development

The utilization of artificial intelligence (AI) in the pharmaceutical industry is developing quickly. In drug development, the use of AI in formulation is a shift from traditional trial-and-error methods to a more data-driven, accelerated approach. AI is being utilized to bridge the gap between drug discovery and clinical trials, optimizing how a molecule is turned into a viable drug product.1

AI is helping to compress drug development timelines by enabling faster data analysis and predictive modeling. Researchers can now design new molecules in weeks rather than months.1 AI-driven workflows for target identification have yielded an average time savings of 28%.

Click Here to Access the Video

About Pharma Fundamentals

Welcome to PharmTech's Pharma Fundamentals video series. Episodes in this educational series aim to provide knowledge in the basics needed for pharmaceutical development and manufacturing, such as chemistry and pharmacology, breaking things down to the basics to help those working in the industry to better perform their jobs. Be sure to check the episode webpage for more topic information and resources. We hope you enjoy the series

About the Speakers

Dr. Christine Allen is Co-Founder and CEO of Intrepid Labs. Dr. Allen is an internationally recognized expert in drug formulation and development, with over 200 peer-reviewed publications. She is a Professor at the University of Toronto and a Fellow of both the American Institute for Medical and Biological Engineering and the Canadian Academy of Health Sciences. She has held numerous leadership roles across academia and industry, including President of the Controlled Release Society and Editor-in-Chief of the Journal of Controlled Release.

Dr. Andrew Lewis is Chief Scientific Officer of Quotient Sciences. As the leader of Quotient Sciences' scientific teams and drug development consultants, Dr. Lewis is responsible for driving efficiency and innovation within our scientific organization, both to better serve our customers and drive growth for the Company.

Andy has over 25 years of experience in the pharmaceutical and drug delivery industry and is a member of the Academy of Pharmaceutical Scientists of Great Britain. Additionally, Andy has served on the board of directors of the Controlled Release Society, most recently as secretary.

Prior to joining Quotient Sciences, Andy was Director of Novel Drug Delivery Technologies at Ipsen. He holds a Ph.D. in Tissue Engineering and a Bachelor of Pharmacy, both from the University of Nottingham.